Anonymous 2005.

Trial name or title	Influence of escitalopram on the incidence of depression and dementia following acute middle cerebral artery territory infarction. A randomised, placebo‐controlled, double‐blind study
Methods	Study type: interventional (clinical trial) Estimated enrolment: 60 participants Allocation: randomised Intervention model: parallel assignment Masking: double (detail unclear) Primary purpose: prevention
Participants	Country: Germany Setting: inpatient Inclusion criteria Acute MCA territory infarction Aiming to recruit 60 over 3 years Within 7 days of stroke onset Prepared to and considered able to follow the whole trial period Exclusion criteria: Dementia Recurrent major depression Major stroke Alcohol and drug dependency Pregnancy, breastfeeding Participating in other trials of medicinal products Impaired liver/kidney disease Life expectancy less than 6 months Aiming to recruit 60 participants
Interventions	Experimental: escitalopram Comparator: placebo
Outcomes	Depression (MADRS) after 180 days Incidence of dementia after 180 days (Clinical Dementia Rating scale) Severity of dementia Zarit Burden Interview Incidence of depression (Depression Visual Analogue Scale) Severity of post‐stroke depression Quality of life (SF‐36) Bayer Activities of Daily Living score NPI
Starting date	MHRA approval 7 April 2006; start date not known
Contact information	Not available. National Competent authority is Germany‐BFarm Sponsor Name: Central Institute for Mental Health, Mannheim, Division of Gerontopsychiatry
Notes	Details available on EudraCT website www.clinicaltrialsregister.eu/ctr‐search/trial/2005‐005266‐37/DE